<DOC>
	<DOCNO>NCT01377597</DOCNO>
	<brief_summary>The purpose study provide efficacy safety data 3 consecutive monthly intravitreal injection 0.5 mg ranibizumab Japanese patient visual impairment due macular edema secondary retinal vein occlusion ( BRVO CRVO ) support applicability phase III study result BRAVO CRUISE indication , Japanese ethnic patient .</brief_summary>
	<brief_title>Efficacy Safety Ranibizumab Japanese Patients With Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Japanese patient diagnose visual impairment exclusively due macular edema secondary either branch retinal vein occlusion ( BRVO ) central retinal vein occlusion ( CRVO ) Diagnosis within 12 month prior Visit 1 Bestcorrected visual acuity ( BCVA ) : CRVO : BCVA score ≥24 ≤73 letter ETDRS ( approx . Snellen equivalent 20/320 20/40 ) Visit 1 2 BRVO : BCVA score ≥19 ≤73 letter ETDRS ( approx . Snellen equivalent 20/400 20/40 ) Visit 1 2 Pregnant nursing woman History stroke Uncontrolled blood pressure Active ocular infection intraocular inflammation either eye Uncontrolled glaucoma either eye Neovascularization iris neovascular glaucoma either eye Prior episode RVO 12 month prior Visit 1 study eye Use systemic antiVEGF drug within 6 month prior Visit 2 Prior treatment antiangiogenic drug within 3 month prior Visit 2 either eye Prior panretinal laser photocoagulation within 3 month prior Visit 2 study eye Prior focal/grid laser photocoagulation within 4 month prior Visit 2 study eye Use intra/periocular corticosteroid within 3 month prior Visit 1 study eye Use intraocular corticosteroid implant study eye Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>retinal vein occlusion</keyword>
	<keyword>branch retinal vein occlusion</keyword>
	<keyword>central retinal vein occlusion</keyword>
	<keyword>visual impairment</keyword>
	<keyword>macular edema</keyword>
	<keyword>ranibizumab</keyword>
</DOC>